NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Inclusion Criteria: 1. Age\>=18 years old 2. cT2 - cT4d, or cT1c with axillary lymph node metastasis confirmed clinically and pathologically； 3. Pathologically proven HR+/HER2- breast cancer: defined as: * positive for ER or PR (IHC nuclear staining \>1%) * Her-2 negative (IHC 0, 1+ without FISH, or IHC 2+ with no amplification by FISH)； 4. Has clinically measurable lesions:Measurable lesions on ultrasound, mammography, or MR (optional) within 1 month before randomization； 5. Organ and bone marrow function tests within 1 month before chemotherapy suggest no contraindications to chemotherapy； 6. Cardiac ultrasound EF value ≧55%； 7. Females of childbearing age, with a negative serum pregnancy test 14 days before randomization; 8. ECOG score≤1 point; 9. Sign informed consent； Exclusion Criteria: 1. The patient has evidence of metastatic breast cancer； 2. For this disease, chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. have been received; 3. The patient has a second primary malignancy other than adequately treated skin cancer; 4. The patient has been treated with anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death ligand 1 (anti-PD-L1) or anti-PD-L2 drugs, or other immunotherapy； 5. The patient has been diagnosed with immunodeficiency disease or autoimmune disease; 6. The patient has severe lung or heart disease; 7. The patient has active hepatitis B and C; 8. The patient has a history of organ transplantation or bone marrow transplantation; 9. pregnant or breastfeeding women; 10. The investigators considered chemotherapy contraindicated due to serious, uncontrolled other medical conditions.